RxDoctor Payments DataLook up a doctor →

Jawan Ayer Cole, MD

Obesity Medicine · Tampa, FLNPI 1841273943

Payments from drug & device makers

$84,865in general payments, 2019–2025

Across 458 payments — averaging $185.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Global Blood Therapeutics, Inc.$36K
  • Pfizer$28K
  • Novartis$10K
  • AstraZeneca$2K
  • Emmaus Medical, Inc.$2K
  • Lilly USA, LLC$2K
  • plus $4K from 38 others

What the payments were for

  • Consulting fees$8,60010%
  • Speaking & faculty fees$58,08268%
  • Travel & lodging$2,9153%
  • Food & beverage$13,05915%
  • Education$5111%
  • Other$1,6982%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$84,865 in reported general payments places this provider in the 95th percentile of 21 obesity medicine providers in Florida.

See all obesity medicine providers in Florida

Medicare billing

Part B allowed, 2024
$212,001
Medicare patients
41
Services billed
15,815

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TasignaNilotinib Hcl20$402,849
OxbrytaVoxelotor25$271,629
VerzenioAbemaciclib12$190,415
BrukinsaZanubrutinib11$167,052
EliquisApixaban106$62,311
OzempicSemaglutide62$58,989
L-GlutamineGlutamine12$30,756
XareltoRivaroxaban37$20,364
MounjaroTirzepatide11$13,344
RetacritEpoetin Alfa-Epbx13$5,689
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen144$3,838
Morphine Sulfate ErMorphine Sulfate96$2,849
Hydroxyurea56$1,580
Fentanyl11$1,029
Hydromorphone Hcl78$964

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisTasigna$9,778$402,84920 claims
Global Blood Therapeutics, Inc.Oxbryta$36,249$271,62925 claims
Lilly USA, LLCVerzenio, Mounjaro$1,736$203,75823 claims
Beigene USA, Inc.Brukinsa$268$167,05211 claims
PfizerEliquis, Retacrit$28,188$68,000119 claims
Novo NordiskOzempic$378$58,98962 claims
Johnson & JohnsonXarelto$693$20,36437 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 21 obesity medicine providers in Florida.

Other obesity medicine in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →